Correction to: Drugs & Therapy Perspectives (2020) https://doi.org/10.1007/s40267-020-00801-2

An Online First version of this article was made available online at https://link.springer.com/article/10.1007/s40267-020-00801-2 on 5 December 2020. An error was subsequently identified in the article, and the following correction should be noted.


Page 4, Table 2, 'Inhibitors of the CGRP pathway' section, ‘Eptinezumab' row: The cell entry in the 'Recommended dosage' column, which previously read:

“100 mg as IV infusion q1mo (may ↑ to 300 mg)”


should read:

“100 mg as IV infusion q3mo (may ↑ to 300 mg)”

The original article has been corrected.